Does Kaiser Cover Zepbound and Wegovy? Wegovy First, Zepbound Rarely

Kaiser Permanente covers Wegovy for weight loss if your Kaiser plan includes a weight-loss drug benefit, and it rarely covers Zepbound. Wegovy is on Kaiser’s 2026 Southern California and Northwest commercial formularies; Zepbound and Mounjaro are not listed on either.^[1][2] In the Northwest, Kaiser’s own criteria say Wegovy is covered for weight loss only for members whose plan covers weight-loss drugs, and both drugs require a documented failure of two older weight-loss medicines first. Zepbound also requires six months on semaglutide and a review by Kaiser’s bariatric medicine team.^[3][4] Kaiser’s Washington plan covers Ozempic, not Wegovy, as its semaglutide for members with a weight-loss rider.^[6] Ozempic is covered for type 2 diabetes across these regions.

Why Kaiser works differently from other insurers

Kaiser is the insurer, the medical group and the pharmacy at once. There is no outside pharmacy benefit manager deciding the drug list; each Kaiser region’s own committee of doctors and pharmacists picks the drugs, and Kaiser clinicians apply the coverage criteria.^[1][2] Two things follow. Your region matters, since Southern California, the Northwest and Washington publish different lists. And a request for a drug that is not on the list starts with your Kaiser doctor, because Kaiser covers a non-formulary drug when a Kaiser doctor or an authorized referral doctor decides it is medically necessary.^[1]

Being on the formulary is not the same as being covered for you. Kaiser’s California list sends members to their Evidence of Coverage for exclusions, and many employer plans leave weight-loss drugs out.^[1] Ask Kaiser Member Services whether your plan includes a weight-loss drug benefit before anything else.

Wegovy in the Northwest: the two-drug step

Kaiser’s Northwest Wegovy criteria, effective November 5, 2026, approve Wegovy or Wegovy HD for 12 months when an adult meets all of these:^[4]

• The plan covers medications used to lose weight. Without that benefit, Kaiser says, members pay the cash price.
• A BMI no lower than 30, or no lower than 27 with a documented condition: hypertension, diabetes, prediabetes, high cholesterol, heart or kidney disease, fatty liver, sleep apnea, osteoarthritis in a weight-bearing joint or polycystic ovary syndrome, with weight and BMI recorded within about the past 30 days.
• Active diet or exercise changes, or a referral to behavioral health for help with them.
• A three-month trial of at least two older weight-loss drugs that did not work, or a reason none of them can be used. The list is phentermine, diethylpropion, topiramate, phentermine with topiramate (Qsymia), and naltrexone with bupropion (Contrave).
• Neither the patient nor a close relative has had medullary thyroid carcinoma or the MEN 2 syndrome.

That older-drug step is the biggest difference from the large commercial insurers. Aetna and Cigna ask for months of lifestyle change but not for other drugs first. If you have already tried phentermine or Qsymia, make sure the dates and the reason you stopped are in your Kaiser chart.

Zepbound at Kaiser: semaglutide first

Zepbound is non-formulary in the Northwest and needs a clinical review. The criteria taking effect December 17, 2026 repeat everything Wegovy requires, including the two older drugs, and then add one more step: a failed trial of semaglutide (Ozempic or Wegovy) of at least six months, followed by a bariatric medicine chart review that decides whether switching to Zepbound is needed. A patient who cannot take semaglutide because of allergy, intolerance or a contraindication can skip that step.^[3] Approval runs 12 months.

Southern California’s 2026 commercial HMO list does not include Zepbound at all, which makes it a non-formulary request there too.^[1] In practice, a Kaiser member who wants Zepbound for weight loss should expect to start on Wegovy.

Sleep apnea: a higher bar than the label

Zepbound’s FDA approval for sleep apnea covers obstructive apnea of moderate or greater severity in people with obesity.^[8] Kaiser’s Northwest criteria cover it only for severe sleep apnea, defined as an apnea-hypopnea index of 30 or more on a sleep study from the past five years, with a BMI of 30 or more, no central or complex apnea, and the same two-drug and semaglutide steps as for weight loss.^[3] The people in the SURMOUNT‑OSA trials averaged around 50 events an hour at the start, so many of them would have qualified, but someone with moderate apnea, between 15 and 29 events an hour, would not.^[10]

Kaiser’s Northwest region also lists criteria for using Wegovy in severe sleep apnea, even though sleep apnea is not among Wegovy’s FDA-approved uses.^[4][9] Kaiser Washington says it covers Ozempic for sleep apnea among other uses.^[6] Our article on Zepbound for sleep apnea explains what the trials measured.

Heart risk and fatty liver

Wegovy is also labeled as heart protection: in people who already have cardiovascular disease and excess weight, it makes heart attacks, strokes and heart-related deaths less likely.^[9] Kaiser’s Northwest criteria for that use are narrow: no diabetes, a BMI of 27 or more, age 55 to 74, and a history of a STEMI or a type 1 NSTEMI, both forms of heart attack. A past stroke or peripheral artery disease alone does not qualify under these criteria.^[4] For MASH, Kaiser asks for a hepatology consult and stage F2 or F3 fibrosis shown by a FibroScan, another elastography scan or a biopsy within the past year.^[4] Our article on GLP‑1 drugs and fatty liver covers the condition.

Ozempic and Mounjaro for type 2 diabetes

Ozempic is on both the Southern California and Northwest lists, including the new Ozempic tablets in the Northwest.^[1][2] Mounjaro is not listed in either region. In the Northwest it is a non-formulary drug with a long step: for most adults with type 2 diabetes, metformin, a sulfonylurea, pioglitazone and an SGLT2 inhibitor, then at least three months each on the top tolerated doses of liraglutide and of semaglutide 2 mg, with an A1C still above 6.9% but below 10%.^[5] Kaiser’s preference for semaglutide runs through its diabetes care as well as its weight care.

Kaiser federal employee plans

Kaiser’s plans for federal employees work differently. Kaiser says its FEHB members can get both GLP‑1 drugs and oral weight-loss drugs at 50% coinsurance, under prior authorization rules that vary by market. Those may include a lifestyle program, a BMI of 27 or more with a related condition, and a failed three-month trial of other weight-loss drugs, followed by monthly check-ins once treatment starts.^[7] Check the brochure for your region.

Kaiser Medicare members

The criteria above are for Kaiser’s commercial plans; the Northwest publishes them as commercial documents.^[3][4] For weight loss alone, people with Medicare drug coverage, Kaiser’s included, look to the federal Medicare GLP‑1 Bridge, a separate program that Medicare runs outside the member’s own plan.

If Kaiser will not cover it

1. Confirm the benefit. Ask Member Services whether your plan covers weight-loss drugs. If it does not, the answer will not change on appeal.
2. Work the steps with your Kaiser doctor. Because Kaiser’s clinicians apply the criteria, the fastest route is often to document the older-drug trials, or the reasons you cannot take them, at your next visit.
3. Ask for a non-formulary exception when Zepbound is medically necessary, for example after a documented failure on Wegovy. If your doctor will not request it, Kaiser’s California list says you can file a grievance with Member Services.^[1] Our guide to prior authorization and appeals covers the federal appeal rights.

Paying cash means leaving Kaiser’s pharmacy, since the manufacturers sell direct. Lilly sells the Zepbound KwikPen and vial from $299 a month, with doses from 7.5 mg at $449 when refilled on time, and Novo Nordisk sells Wegovy pens for $349 a month at most doses and the Wegovy pill from $149.^[11][12] Our Wegovy pill price guide and our ranking of the cheapest GLP‑1 without insurance compare the options.